MCK Stock Overview
Provides healthcare services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
PRISM Vision Acquisition Will Expand Specialty Services In Retina And Ophthalmology
McKesson Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$683.11 |
| 52 Week High | US$728.32 |
| 52 Week Low | US$464.42 |
| Beta | 0.49 |
| 1 Month Change | 6.80% |
| 3 Month Change | 18.30% |
| 1 Year Change | 26.80% |
| 3 Year Change | 109.65% |
| 5 Year Change | 412.38% |
| Change since IPO | 4,040.06% |
Recent News & Updates
Recent updates
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
Mar 25McKesson Seems Cheap, But Risks Linger
Jan 21Investors Still Waiting For A Pull Back In McKesson Corporation (NYSE:MCK)
Dec 19
McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture
Nov 14McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Nov 09McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Oct 09McKesson: The Correction Is Not Over
Sep 10McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing
Aug 22McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson: Why The Company Is Too Richly Valued
Jan 19McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08McKesson: Still Trading For A Huge Discount
Sep 06McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08Shareholder Returns
| MCK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.3% | -0.5% | -9.5% |
| 1Y | 26.8% | 0.9% | -3.3% |
Return vs Industry: MCK exceeded the US Healthcare industry which returned 5.4% over the past year.
Return vs Market: MCK exceeded the US Market which returned 3.3% over the past year.
Price Volatility
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 3.2% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: MCK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MCK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
McKesson Corporation Fundamentals Summary
| MCK fundamental statistics | |
|---|---|
| Market cap | US$89.85b |
| Earnings (TTM) | US$2.83b |
| Revenue (TTM) | US$344.58b |
30.3x
P/E Ratio0.2x
P/S RatioIs MCK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCK income statement (TTM) | |
|---|---|
| Revenue | US$344.58b |
| Cost of Revenue | US$331.46b |
| Gross Profit | US$13.12b |
| Other Expenses | US$10.30b |
| Earnings | US$2.83b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 22.55 |
| Gross Margin | 3.81% |
| Net Profit Margin | 0.82% |
| Debt/Equity Ratio | -289.1% |
How did MCK perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/04 11:00 |
| End of Day Share Price | 2025/04/04 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
McKesson Corporation is covered by 42 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |